Splendris International Ltd., of Shenzhen, China, an affiliate of Shenzhen Salubris Pharmaceuticals Co. Ltd., inked an investment and in-licensing agreement with Swiss firm Medalliance SA under which Salubris will make a $20 million equity investment in Medalliance and will commit an additional $10 million in development milestones in exchange for exclusive rights to develop and commercialize Medalliance's lead product, Selution, a sirolimus micro-reservoir drug-coated balloon, for peripheral and cardiovascular applications in the Chinese market.